Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer
Our findings indicate that disrupting the β-catenin/BCL9 interaction with a peptide-based nanoprodrug represents a compelling strategy to suppress oncogenic signaling and enhance immunotherapy responses in CRC, providing a new angle to boost checkpoint sensitivity.
Authors
- Xiao Shang (ORCID: https://orcid.org/0000-0002-2524-4007)
- Weiming You
- Jinmei Wang (ORCID: https://orcid.org/0000-0002-3850-1893)
- Peili Wang (ORCID: https://orcid.org/0000-0001-6596-3797)
- Shuai Qu
- Yu Yao
- X. X. Zheng
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1662385
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China